Next Post

Celyad Oncology Announces First Quarter 2022 Financial Results and Recent Business Highlights

Enrollment proceeds in Section 1 dose-escalation IMMUNICY-1 demo for guide shRNA-dependent allogeneic Motor vehicle T applicant, CYAD-211, for relapsed/refractory numerous myeloma (r/r MM) Dialogue continues with regulatory businesses about CYAD-101-002 Section 1b trial, which remains on scientific maintain MONT-SAINT-GUIBERT, Belgium, Might 05, 2022–(Organization WIRE)–Regulatory News: This replaces the announcement manufactured […]

You May Like